



## Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

March 23, 2022

*Guggenheim Genomic Medicines and Rare Disease Conference on April 1, 2022 at 4:00 pm ET*

*21<sup>st</sup> Annual Needham Virtual Healthcare Conference April 11, 2022 at 11:45 am ET*

DALLAS--(BUSINESS WIRE)--Mar. 23, 2022-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in upcoming fireside chats at the Guggenheim Genomic Medicines and Rare Disease Day Conference and the 21<sup>st</sup> Annual Needham Virtual Healthcare Conference.

### Conference Details:

Event: Guggenheim Genomic Medicines and Rare Disease Day Conference  
Date: April 1, 2022  
Time: 4:00 pm ET  
Format: Fireside Chat  
Participants: RA Session II, President, Founder and CEO  
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D  
Kamran Alam, Chief Financial Officer

### Conference Details:

Event: 21<sup>st</sup> Annual Needham Virtual Healthcare Conference  
Date: April 11, 2022  
Time: 11:45 am ET  
Format: Fireside Chat  
Participants: RA Session II, President, Founder and CEO  
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D  
Kamran Alam, Chief Financial Officer

### About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients' lives. More information is available at [www.tayshagtx.com](http://www.tayshagtx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220323005345/en/): <https://www.businesswire.com/news/home/20220323005345/en/>

### Company Contact:

Kimberly Lee, D.O.  
Chief Corporate Affairs Officer  
Taysha Gene Therapies  
[klee@tayshagtx.com](mailto:klee@tayshagtx.com)

### Media Contact:

Carolyn Hawley  
Canale Communications  
[carolyn.hawley@canalecomm.com](mailto:carolyn.hawley@canalecomm.com)

Source: Taysha Gene Therapies, Inc.